December 3, 2019 10:50 AM ESTUpdated December 4, 04:40 AM
R&D

Bio­gen boasts PhII win in lu­pus — will any­one turn their head from Alzheimer's to no­tice?

Amber Tong

As the gaze on ad­u­canum­ab in­ten­si­fies in the runup to Bio­gen’s hot­ly-an­tic­i­pat­ed da­ta pre­sen­ta­tion at an Alzheimer’s con­fer­ence this week, the biotech is of­fer­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times